Michael Guy, MD
Gynecologic Oncology · Kettering, OHNPI 1174773287
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by Merck at 54.7% of the total.
Across 34 payments — averaging $138.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Intuitive Surgical$2K
- Davol Inc.$145
- Novocure Inc.$58
- Eisai Inc.$19
- Tempus AI, Inc$17
- plus $29 from 2 others
Across 78 payments — averaging $7699.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$506K
- Novocure Inc.$67K
- AstraZeneca$27K
What the payments were for
- Travel & lodging$2,80059%
- Food & beverage$1,90841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 14 | $2,576 |
| Intuitive Surgical | 14 | $1,864 |
| Davol Inc. | 1 | $145 |
| Novocure Inc. | 1 | $58 |
| Eisai Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,599
- MK-7339$967
- Phasix Mesh$145
How this compares
$4,708 in reported general payments places this provider in the 70th percentile of 62 gynecologic oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 41 | $583,902 |
| ZejulaNiraparib Tosylate | 19 | $357,258 |
| Everolimus | 20 | $132,343 |
| Ondansetron Hcl | 41 | $3,854 |
| Prochlorperazine Maleate | 31 | $812 |
| Dexamethasone | 33 | $564 |
| Olanzapine | 39 | $398 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 23 | $263 |
| Ondansetron OdtOndansetron | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Kettering
- Juliet WolfordKettering$11K
- David OmalleyHilliard$650K
- Thomas HerzogCincinnati$585K
- Floortje BackesHilliard$181K
- Adam WalterSylvania$137K
- Amanda JacksonCincinnati$92K
- Amelia JerniganCleveland$85K
- Casey CosgroveHilliard$30K
- Kimberly ResnickCleveland$29K
- Robert NeffHilliard$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.